Payers are increasingly reliant on ICER reports for their formulary decision making process. Join this webinar on Tuesday, September 15, at 2-3pm ET as expert stakeholders discuss what payers find most relevant when it comes to ICER, the impact ICER reports have on coverage decisions, and how […]
How Can Employers Make Pricey Gene Therapies and Specialty Drugs Less Costly?
A recent survey found that several large American firms plan to employ a variety of strategies to mitigate expenses and possibly erect barriers to access for new drugs whose costs can run in the seven figures. For example, employers can delay putting drugs on their formulary until safety and […]
How Can Excessive Price Increases Be Better Regulated?
Much of the overall spending on prescription drugs in the United States can be attributed to price increases, resulting in penalties being imposed on drugmakers for excessive price increases . Despite high launch prices, many prices for single-source (branded) drugs increase above the rate of […]
Cost-Sharing Waivers for COVID-19 Treatment Are Expiring
Cost-sharing waivers for COVID-19 treatment are due to expire in the upcoming months. Approximately 88% in individual and fully insured group markets have plans that limit out-of-pocket costs for COVID-19 treatment. After factoring waivers that have already expired, roughly 50% of enrollees in such […]
Pharma14 adds South Korea to Global Medicine and Pricing Database
The pharmaceutical market in South Korea is undergoing rapid expansion and expected to reach more than US$ 21 billion by 2021, up from 18.6 billion USD in 2016. Forecasters expect a compounded annual growth rate of over 7% due to the South Korean government’s increasing focus on generics as a […]
Webinar Recap: It’s Time to Talk About COVID-19 Prices
Join National Pharmaceutical Council Chief Science Officer Robert Dubois, Memorial Sloan Kettering Cancer Center's Peter Bach, Institute for Clinical and Economic Review's Sarah Emond, Northwestern University's Craig Garthwaite and Tufts University's Peter Neumann for a discussion of the tremendous […]
- Previous Page
- 1
- …
- 37
- 38
- 39
